DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Tay-Sachs disease — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTay-Sachs disease maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for tay-sachs disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ganglioside GM2 activator (GM2A) — GM2A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 7rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2AG4 · 1.8 Å · ligand (7R)-4,7-DIHYDROXY-N,N,N-TRIMETHYL-10-OXO-3,5,9-TRIOXA-4-PHOSPHAHEPTACOSAN-1-AMINIUM 4-OXIDE (LP3). Experimental structure, not a prediction.
What the evidence adds up to
Tay-Sachs disease is a fatal autosomal recessive disorder caused by mutations in the HEXA gene, leading to deficient beta-hexosaminidase A enzyme activity and accumulation of gangliosides in neuronal cells. The disease primarily affects the central nervous system, resulting in progressive neurological degeneration. Clinical manifestations include infantile, juvenile, and adult-onset forms. In 1971, researchers at the National Institute of Neurological Diseases and Stroke described the disease as caused by an abnormal gene responsible for the absence of a specific enzyme, with accumulation of lipid material in nerve cells of the brain and other body cells destroying cells and causing severe mental retardation and eventual death.
A 1993 study of 19 non-Jewish Tay-Sachs patients (7 with adult or late onset, 12 with infantile disease) used cDNA-PCR amplification of beta-hexosaminidase mRNA from cultured fibroblasts, screening the HEXA gene with chemical mismatch cleavage, denaturing gradient gel electrophoresis, and direct sequencing. These methods identified 31 out of 38 alleles studied (82%). In addition to 9 previously described mutations (the 4 bp insertion in exon 11, G to A transitions at codons 170, 269, 482, 499 and 504, C to T transition at codon 499 and 504, and a GT to AT transition at the donor site of intron 9), 10 novel mutations were identified: 1 donor splice site defect in intron 6, 8 missense mutations at non-randomly distributed conserved residues, and a 2 bp deletion in exon 4. These results confirm extreme molecular heterogeneity of mutations causing Tay-Sachs disease in the non-Jewish population.
A 2024 review article lists emerging therapeutic strategies such as enzyme replacement therapy, substrate reduction therapy, and gene therapy, stating these advances provide hope for altering the disease's course in the future. No clinical trial data, survival figures, or response rates from any of these strategies are reported in the abstracts provided. The 1971 paper predicted complete eradication of Tay-Sachs disease in the near future, but that has not occurred.
What is still missing: no clinical trial results for any therapy in patients, no evidence that enzyme replacement, substrate reduction, or gene therapy have been tested in humans with Tay-Sachs, no data on patient stratification by mutation type or age of onset, and no funding commitments for the necessary trials to move from genetic characterisation to treatment.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Human Molecular Genetics · 1993 · 37 citations
Ten novel mutations in the HEXA gene in non-Jewish Tay — Sachs patients
AbstractThe heterogeneity of mutations causing Tay-Sachs disease in non-Jewish populations requires efficient techniques allowing the simultaneous screening for both known and novel mutations. beta-hexosaminidase mRNA isolated from cultured fibroblasts of 19 Tay-Sachs patients (7 with adult or late onset form of the disease and 12 with infantile Tay-Sachs disease) was amplified by cDNA-PCR in two overlapping segments spanning the entire coding sequence. We used chemical mismatch cleavage (CMC), denaturing gradient gel electrophoresis (DGGE) and direct sequencing of amplified fragments displaying a cleaved product or an altered melting behavior to screen the HEX A gene for mutations and to determine their distribution and frequency in the non-Jewish Tay-Sachs patients. These methods allowed us to identify 31 out of 38 alleles studied (82%). In addition to 9 previously described mutations (the 4 bp insertion in exon 11, G to A transitions at codons 170, 269, 482, 499 and 504, C to T transition at codon 499 and 504 and a GT to AT transition at the donor site of intron 9), we have identified 10 novel mutations. These include 1 donor splice site defect in intron 6, 8 missense mutations at non-randomly distributed conserved residues and a 2 bp deletion in exon 4. These results confirm the extreme molecular heterogeneity of mutations causing Tay-Sachs disease in non-Jewish population. The strategy used should be profitable for identifying mutations in large genes and for diagnostic purposes.
HSMHA Health Reports · 1971 · 1 citations · open access
Tay-Sachs and Other Lipid Storage Diseases
AbstractRarely does medical science advance in a relatively short time from little knowledge about a disease to foreseeing its complete eradication in the not-so-distant future, particularly when that dis- ease is an inherited genetic disor- der.Yet, this is precisely the out- look for Tay-Sachs disease.A host of researchers including physicians and scientists at the National Institute of Neurological Diseases and Stroke, a compo- nent of the National Institutes of Health, have cracked the mystery of Tay-Sachs disease and are working steadily to eliminate it from the list of neurological dis- orders that plague man.Caused by an abnormal gene which is responsible for the ab- sence of a specific enzyme, Tay- Sachs disease is characterized by the accumulation of lipid mate- rial in the nerve cells of the brain and in other body cells.This ac- cumulation of fatty material (sphingolipids) destroys the cells, thus causing severe mental retar- dation and eventual death.
Tay-Sachs Disease and HEXA Gene Mutations _ Genome Disfunction Review
AbstractTay-Sachs disease is a fatal autosomal recessive disorder caused by mutations in the HEXA gene, leading to the accumulation of gangliosides in neuronal cells due to deficient beta-hexosaminidase A enzyme activity. This lysosomal storage disorder primarily affects the central nervous system, resulting in progressive neurological degeneration. This article examines the genetic basis of Tay-Sachs disease, its clinical manifestations across infantile, juvenile, and adult-onset forms, and emerging therapeutic strategies such as enzyme replacement therapy, substrate reduction therapy, and gene therapy. These advances provide hope for altering the disease's course in the future.
Tay-Sachs Disease and HEXA Gene Mutations _ Genome Disfunction Review
AbstractTay-Sachs disease is a fatal autosomal recessive disorder caused by mutations in the HEXA gene, leading to the accumulation of gangliosides in neuronal cells due to deficient beta-hexosaminidase A enzyme activity. This lysosomal storage disorder primarily affects the central nervous system, resulting in progressive neurological degeneration. This article examines the genetic basis of Tay-Sachs disease, its clinical manifestations across infantile, juvenile, and adult-onset forms, and emerging therapeutic strategies such as enzyme replacement therapy, substrate reduction therapy, and gene therapy. These advances provide hope for altering the disease's course in the future.
AbstractTay-Sachs disease is a hereditary neurodegenerative disorder resulting from excess storage of GM2 ganglioside within the lysosomes of cells. The incidence of the disease is estimated to be 1 in 3600 in Ashkenazi Jews with carrier frequency of 1 in 30 and 1 in 360,000 in other population with carrier frequency of 1 in 300. Tay-Sachs disease is the most frequently occurring sphingolipidoses.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
